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Abstract: Three new norzoanthamine-type alkaloids, named 2-hydroxy-11-ketonorzoan 
thamide B (1), norzoanthamide B (2) and 15-hydroxynorzoanthamine (3), were isolated 
from Zoanthus sp. specimens collected at the Canary Islands. Their structures were 
determined by interpretation of NMR and HR-ESIMS data. Relative configurations of their 
chiral centers were proposed on the basis of ROESY spectra and by comparison of their 
spectroscopic data with those of the well-known compound, norzoanthamine. 
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1. Introduction 
Marine zoanthids are widely dispersed throughout the temperate and tropical littoral regions of  
the Indic, Pacific and Atlantic Oceans. Diverse species of these organisms produce a wide array of 
metabolites, some of which have unique structures and possess significant biological activities [1].  
In particular, from the genus Zoanthus (phylum Cnidaria, class Anthozoa, order Zoanthidea), different 
research groups have isolated a series of alkaloids, known as zoanthamines, characterized by a unique 
polycyclic backbone [2]. Zoanthamine, isolated in 1984 from polyps collected at the Visakhapatnam 
coast of India by Faulkner et al. [3], was the first example of these compounds. Afterwards, 
norzoanthamine was identified from a colony of polyps collected at the Ayamaru coast of the Amami 
Island, South Japan, by Uemura and co-workers [4]. Later, other research groups reported a significant 
number of related compounds, some of which have substantial structural modifications [5–9]. From a 
pharmacological point of view, different biological effects, including anti-inflammatory, antiplatelet 
and antiosteoporotic activities, have been investigated [10–12]. In particular, the increasing worldwide 
prevalence of osteoporosis and the novel mechanism of action of zoanthamines have set them up as 
promising drug candidates [13]. Accordingly, a number of synthetic approaches to obtain these 
molecules independently from organism collection have been published [14–16]. 
In this paper, we describe the isolation and structural characterization of three new oxidized 
norzoanthamine congeners from the genus Zoanthus collected at the coast of Tenerife. The structures 
of these new metabolites, 2-hydroxy-11-ketonorzoanthamide B (1), norzoanthamide B (2) and  
15-hydroxynorzoanthamine (3), were determined primarily on the basis of MS and NMR data  
(Figure 1). 
Figure 1. Structures of three new zoanthamine-type alkaloids isolated from Zoanthus sp. 
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2. Results and Discussion 
Colonies of Zoanthus sp. were collected by hand in the intertidal zone of Punta del Hidalgo, 
Tenerife, Canary Islands (28°34′35.06ʺ N; 16°19′43.64ʺ W) (Figure 2). Fresh specimens (120 g) were 
extracted with MeOH (3 × 2 L each time) at room temperature and the solvent removed in vacuo to 
give a brownish viscous oil (1.9 g). The extract was chromatographed on a Sephadex LH-20 column  
(3-cm internal diameter and 20-cm length) using MeOH and collecting 60 tubes of 10 mL. A second 
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chromatographic step included a Lobar LiChroprep-RP18 column using MeOH:H2O (7:3) as the eluent  
at 2 mL/min flux. Two fractions, obtained between 8–16 min and 17–25 min, were further purified by 
HPLC using a μ-Bondapack C-18 column and CH3CN:MeOH:H2O (2:1:1) or (2:1:2), respectively, as 
mobile phases at 2 mL/min. This procedure yielded 0.50 mg of 2-hydroxy-11-ketonorzoanthamide B (1), 
0.45 mg of norzoanthamide B (2) and 0.30 mg of 15-hydroxynorzoanthamine (3), together with the 
previously known norzoanthamine, zoaramine and zoarenone [9]. 
Figure 2. Colonies of Zoanthus sp. (Photos courtesy of Alberto Brito). 
  
2-Hydroxy-11-ketonorzoanthamide B (1) was isolated as an optically active powder [α]25D +9  
(c 0.045, CHCl3). Its molecular formula was established by ESI-HRMS as C29H35NO8 (m/z 526.24340; 
calculated for 526.24354, C29H36NO8, [M + H]+), requiring thirteen degrees of unsaturation. The  
1H NMR spectrum of 1 showed a number of signals characteristic norzoanthamine, including four 
methyl singlets at δH 1.01, 1.03, 1.34 and 2.01, one methyl doublet at δH 1.00, the AX system 
corresponding to CH2-23 (δH 2.55 and 4.27, J = 20.6 Hz), as well as the distinctive olefinic methine 
proton at δH 5.90 (s). Analysis of the HSQC and HMBC experiments allowed us to classify the existent 
29 carbon signals as five methyls, seven methylenes, five methines and twelve quaternary carbons, 
including two carboxylic and three carbonyl carbons at δC 168.1, 170.6, 195.8, 197.9 and 206.9  
(Table 1). 
Analysis of the COSY spectrum revealed the presence of three isolated 1H-1H spin-systems (I–III 
as showed in Figure 3). The first system (Fragment I) includes methyl CH3-30 (δH 1.00, d, J = 6.0 Hz;  
δC 20.9), which is coupled with CH-4 (δH 2.05; δC 24.5) and this, in turn, with both CH2-3  
(δH 1.43/2.03; δC 38.0) and CH2-5 (δH 1.15/2.05; δC 40.3). Fragment II includes only methylenes CH2-7  
(δH 1.92/2.14; δC 28.7) and CH2-8 (δH 1.70/1.86; δC 23.8). Finally, Fragment III was started from 
methylene CH2-14 (δH 2.17/2.98; δC 32.7) that is coupled with CH-13 (δH 2.76; δC 46.7), in turn, 
connected with CH-18 (δH 2.70; δC 46.0) and CH2-19 (δH 2.48/2.67; δC 42.7) (Figure 3). The significant 
number of quaternary carbons existent within this molecule made the HMBC experiment an essential 
tool to connect them with the previously described 1H-1H spin-systems. Thus, HMBC correlations of 
H2-3 with carbon C-1 (δC 170.6) and C-2 (δC 100.6), together with the cross-peaks of H2-5 and H2-7 
with C-6 (δC 90.2), allowed us to establish a seven-membered lactam ring. The chemical shifts of C-2 
and C-6 indicated that both are ketal carbons and allowed us to build the azabicycle [3.2.1] system 
present in this new metabolite. In addition, the HMBC correlations observed from methines H-16  
Mar. Drugs 2014, 12 5191 
 
 
(δH 5.90, s) and H-21 (δH 2.89, s), as well as those from methyls CH3-25, CH3-27, CH3-28 and CH3-29 
resulted in it being very valuable to build the polycyclic core of the molecule (Figure 3). 
The relative configuration of 1 was deduced by analysis of the ROESY spectrum and 1H-1H 
coupling constants values together with a comparison of its chemical shift values with those of 
norzoanthamine. Particularly important were the dipolar correlations between H-21 (δH 2.89) and H-13 
(δH 2.76), H3-25 (δH 1.01) and H3-29 (δH 1.03) together with those of H-18 (δH 2.70) and H3-28  
(δH 1.34), which allowed us to propose a 2R*, 4R*, 6S*, 9S*, 10S*, 12S*, 13R*, 18S*, 21R*, 22S*, 23S* 
relative configuration for 1 (Figure 3). 
Figure 3. (Left) HMBC correlations for 2-hydroxy-11-ketonoroanthamide B (1) are 
indicated by arrows. 1H-1H spin systems I–III are showed in bold blue lines;  
(Right) significant dipolar correlations observed in the ROESY spectrum are indicated by a 
dotted blue line. 
  
Table 1. NMR data (CDCl3) for 2-hydroxy-11-ketonorzoanthamide B (1). 
2-Hydroxy-11-ketonorzoanthamide B (1) 
C δ 13C δ 1H J (Hz) C δ 13C δ1H J (Hz) 
1 170.6, C - - 16 124.5, CH 5.90 s 
2 100.6, C - - 17 197.9, C - - 
3 38.0, CH2 1.43 (β); 2.03 (α) 11.2; 12.0 m 18 46.0, CH 2.70 5.8; 11.3; 12.0 
4 24.5, CH 2.05 m 19 42.7, CH2 2.48 (β); 2.67 (α) 
11.3; 13.3; 
5.8; 13.3 
5 40.3, CH2 1.15 (); 2.05 (α) 12.3; 14.8 m 20 206.9, C - - 
6 90.2, C - - 21 60.8, CH 2.89 s 
7 28.7, CH2 1.92 (α); 2.14 (β) 
2.9; 4.0; 13.7; 
3.1; 12.1; 13.7 
22 38.1, C - - 
8 23.8, CH2 1.70 (β); 1.86 (α) 
3.1; 4.0; 13.4; 
2.9; 12.1; 13.4 
23 34.6, CH2 2.55 (β); 4.27 (α) 20.6; 20.6 
9 43.9, C - - 24 168.1, C - - 
10 95.7, C - - 25 20.9, CH3 1.01 s 
11 195.8, C - - 27 24.4, CH3 2.01 s 
12 54.9, C - - 28 14.1, CH3 1.34 s 
13 46.7, CH 2.76 3.6; 10.3; 12.0 29 17.7, CH3 1.03 s 
14 32.7, CH2 2.17 (β); 2.98 (α) 
10.3; 18.2; 3.6; 
18.2 
30 20.9, CH3 1.00 6.0 
15 162.2, C - -     
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Table 2. NMR data (CDCl3) for norzoanthamide B (2) and 15-hydroxynorzoanthamine (3). 
C 
Norzoanthamide B (2) 15-Hydroxynorzoanthamine (3) 
δ 13C δ1H J (Hz) δ 13C δ1H J (Hz) 
1 175.0, C - - 47.1, CH2 3.23; 3.25 m 
2 77.0, CH 4.25 2.1; 3.6 74.2, CH 4.55 m 
3 32.7, CH2 1.41 (β); 1.86 (α) 
3.6; 12.0; 13.5; 2.1; 
4.5; 13.5 
38.8, CH2 1.46; 1.55 m 
4 23.8, CH 2.22 4.2; 4.5; 11.1; 12.0 22.9, CH 2.27 6.0; 11.1 
5 40.8, CH2 1.18 (β); 2.19 (α) 11.1; 13.2; 4.2; 13.2 44.4, CH2 1.08 (β); 2.08 (α) 
11.1; 14.0; 
6.0; 14.0 
6 93.4, C - - 89.9, C - - 
7 29.8, CH2 1.90 (α); 2.08 (β) 
3.1; 4.2; 13.5; 5.6; 
13.3; 13.5 
29.9, CH2 1.76; 1.89 m 
8 22.6, CH2 1.63; 1.65 m 23.7, CH2 1.55; 1.67 m 
9 39.8, C - - 39.9, C - - 
10 96.6, C - - 102.0, C - - 
11 40.2, CH2 2.30; 3.52 15.2; 15.2 42.1, CH2 1.90 (β); 2.13 (α) 14.0; 14.0 
12 39.4, C - - 35.8, C - - 
13 53.3, CH 2.22 4.0; 12.0; 12.1 51.6, CH 2.35 m 
14 31.6, CH2 2.31 (β); 2.44 (α) 12.1; 17.9; 4.0; 17.9 37.8, CH2 1.61 (β); 1.87 (α) m 3.0; 13.4 
15 160.8, C - - 73.7, C - - 
16 125.3, CH 5.90 s 54.4, CH2 2.46; 2.54 13.8; 13.8 
17 198.3, C - - 207.0, C - - 
18 46.2, CH 2.70 5.5;11.3;12.0 50.4, CH 2.73 m 
19 42.3, CH2 2.51 (β); 2.66 (α) 11.3; 13.7; 5.5; 13.7 42.3, CH2 2.34 (β); 2.73 (α) m 
20 208.7, C - - 209.6, C - - 
21 58.5, CH 2.83 s 59.4, CH 2.91 s 
22 36.1, C - - 36.4, C - - 
23 36.1, CH2 2.43 (β); 3.70 (α) 20.6; 20.6 36.0, CH2 2.36; 3.62 20.4; 20.4 
24 169.9, C - - 172.3, C - - 
25 20.8, CH3 1.04 s 18.4, CH3 0.99 s 
27 24.3, CH3 2.10 s 31.4, CH3 1.45 s 
28 18.0, CH3 0.97 s 18.0, CH3 1.00 s 
29 17.0, CH3 1.22 s 18.4, CH3 1.17 s 
30 21.3, CH3 0.99 6.4 21.9, CH3 0.91 6.6 
Norzoanthamide B (2) was isolated as an optically active powder, [α]25D +10 (c 0.03, CHCl3),  
and its molecular formula was established as C29H37NO6 on the basis of the result obtained from  
ESI-HRMS (m/z 496.26918; calculated for 496.26936, C29H38NO6, [M + H]+). MS data were further 
supported by analysis of NMR data. Thus, five CH3, eight CH2 and six CH, as well as ten quaternary 
carbons (including two carboxylic, two carbonyl and two olefinic carbons) were identified (Table 2). 
Comparative analysis of the NMR data of 2 with those of norzoanthamine allowed us to conclude that 
C-1 is now the carboxylic signal at δC 174.5. Further analyses of COSY, HSQC and HMBC spectra 
confirmed our previous conclusion. Consequently, an azabicycle [3.2.1] system was built starting from 
methine CH-2 (δH 4.25; δC 77.0) and sequentially to CH2-3 (δH 1.41/1.86; δC 32.7), CH-4 (δH 2.22;  
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δC 23.8) and, finally, with both CH2-5 (δH 1.18/2.19; δC 40.7) and methyl CH3-30 (δH 0.99; δC 21.3).  
In addition, the HMBC connectivity of proton H-2 with the signal at δC 174.5 supported the existence  
of a lactam within this ring. The relative configuration of norzoanthamide B (2) was proposed to be  
2R*, 4S*, 6S*, 9S*, 10S*, 12S*, 13R*, 18S*, 21R*, 22S*, 23S* based on the correlations observed in the 
ROESY experiment and supported by a comparison with the chemical shift data reported  
for norzoanthamine. 
15-Hydroxynorzoanthamine (3) was obtained as a solid, [α]25D +8 (c 0.03, CHCl3). The molecular 
formula of 3 was deduced by ESI-HRMS as C29H41NO6 (m/z 500.30050; calculated for 500.30066,  
[M + H]+), therefore indicating the presence of an additional oxygen atom with respect to norzoanthamine. 
Comparison of the NMR data of 3 with those reported for norzoanthamine clearly revealed that the new 
metabolite shares the same carbon skeleton, but contains an additional oxygen atom attached to C-15 
(Table 2). This is in accordance with the absence of the characteristic olefin carbons C-15 and C-16, as 
well as with the presence of two new signals at δC 73.6 and δC 54.4 corresponding to a tertiary hydroxyl 
at C-15 and a new methylene at C-16 (δH 2.46/2.54, d, J = 13.8 Hz), respectively (Table 2). These 
findings were supported by the absence of the α,β-unsaturated ketone distinctive absorption band in the 
UV spectrum. Analysis of the ROESY experiment confirmed that the relative configurations of all chiral 
centers in 3 are equivalent to those observed in norzoanthamine. The relative configuration of the new 
stereogenic center at C-15 was established as R* on the basis of the cross-correlation peak between  
CH3-27 (δH 1.45) and both CH2-14 (δH 1.61/1.87) and CH2-16 (δH 2.46/2.54) observed in the ROESY 
spectrum (Figure 4). 
Figure 4. Relevant dipolar correlations observed for 15-hydroxynorzoanthamine (3) 
(dotted blue line) and a selected fragment of the ROESY spectrum. 
  
3. Experimental Section  
3.1. General Methods 
Optical rotations were measured at room temperature in CHCl3 using a sodium lamp. Low and high 
resolution ESI-MS were recorded on a Micromass LTC Premier XE system mass spectrometer (Waters, 
Milford, CT, USA). NMR spectra were recorded on a Bruker AVANCE III 600 MHz (Bruker, 
Rheinstetten, Germany) equipped with a 5-mm TCI inverse detection cryo-probe (Bruker, Rheinstetten, 
Germany). 1H and 13C NMR chemical shifts were referenced either to the CDCl3 peaks at 300 K. 
COSY, TOCSY, multiplicity-edited HSQC, HMBC and ROESY experiments were performed using 
standard pulse sequences. HSQC, TOCSY and ROESY experiments were performed in the phase-sensitive 
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mode (States-TPPI or Echo-AntiEcho for quadrature detection in F1) and used gradient coherence 
selection. 3JH,H values were measured from 1D 1H NMR. TOCSY experiment was recorded using DIPSI 
during the 50 ms of the isotropic mixing period. The ROESY experiment was recorded using a spin-lock 
generated by two 180° hard pulses during 400 ms in order to avoid TOCSY artefacts. The HMBC was 
optimized to detect long-range correlations using a value of 6 Hz. Prior to Fourier transformation, zero 
filling was performed to expand the data to at least double the number of acquired data points. HPLC 
separations were carried out with a preparative silica column (10 μ, 19 × 150 mm) (Waters, Milford, CT, 
USA) and a photodiode array detector (Waters, Milford, CT, USA). TLC plates were visualized by 
spraying with Dragendorff reagent and phosphomolybdic acid (10% in EtOH), followed by heating. 
3.2. Biological Material 
Colonies of Zoanthus sp. were collected by hand in the intertidal zone of Puntal del Hidalgo, 
Tenerife, Canary Islands (28°34′35.06ʺ N; 16°19′43.64ʺ W). A specimen was deposited at the 
Department of Animal Biology of University of La Laguna, Tenerife, and classified by Alberto Brito 
at the University of La Laguna (La Laguna, Tenerife). 
3.3. Extraction and Chromatographic Separation 
Fresh specimens (120 g) were extracted with MeOH (three times using 2 L each time) at room 
temperature and the solvent removed in vacuo to give a brownish viscous oil (1.9 g). The extract was 
chromatographed on a Sephadex LH-20 column (3 cm of internal diameter and 20 cm of length) (GE 
Healthcare, Buckinghamshire, UK) using MeOH, collecting 60 tubes of 10 mL, and subsequently with 
Lobar LiChroprep-RP18 (Merck, Darmstadt, Germany) with MeOH:H2O (7:3) as the eluent at 2 mL/min 
flux. The fractions collected between 8 and 16 min were polled together and further purified by HPLC 
using a μ-Bondapack C-18 column (Waters, Milford, CT, USA), employing CH3CN:MeOH:H2O (2:1:1) 
as the mobile phase at 2 mL/min to obtain norzoanthamide B (2) (0.45 mg; 15–17 min). In addition, 
fractions polled from the Lobar LiChroprep-RP18 chromatographic step (Merck, Darmstadt, Germany) 
between 17 and 25 min were further purified by HPLC using a μ-Bondapack C-18 column, employing 
CH3CN:MeOH:H2O (2:1:2) as the eluent at 2 mL/min to yield 2-hydroxi-11-ketonorzoanthamide B (1) 
(0.5 mg; 15–18 min) and 15-hydroxynorzoanthamine (3) (0.3 mg; 22–24 min). 
2-Hydroxy-11-ketonorzoanthamide B (1): white powder; [α]25D +9 (c 0.045, CHCl3); UV λmax 
(CHCl3) 239.8 (ε 1,630) (log ε = 3.2); IRνmax (CHCl3) 3384, 2927, 2857, 1742, 1723, 1669, 1383, 
1220 and 1008 cm−1; ESI-HRMS m/z 526.24340 (calculated for C29H36NO8, 526.24354, [M + H]+); 1H 
(600 MHz, CDCl3) and 13C (150 MHz, CDCl3) NMR chemical shifts are reported in Table 1. 
Norzoanthamide B (2): white powder; [α]25D +10 (c 0.03, CHCl3); UV λmax (CHCl3) 239.8  
(ε 1630) (log ε = 3.2); IRνmax (CHCl3) 3455, 2926, 2856, 1726, 1465, 1383 and 1246 cm−1; ESI-HRMS 
m/z 496.26918 (calculated For C29H38NO6, 496.26936, [M + H]+); 1H (600 MHz, CDCl3) and 13C  
(150 MHz, CDCl3) NMR chemical shifts are reported in Table 2. 
15-Hydroxynorzoanthamine (3): white powder; [α]25D +8 (c 0.03, CHCl3); IRνmax (CHCl3) 3414, 
2924, 2854, 1715, 1665, 1377, 1240 and 1217 cm−1; ESI-HRMS m/z 500.30050 (calculated for 
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C29H42O6N, 500.30066, [M + H]+); 1H (600 MHz, CDCl3) and 13C (150 MHz, CDCl3) NMR chemical 
shifts are reported in Table 2. 
4. Conclusions 
The structures of three new congeners of norzoanthamine have been elucidated by means of MS 
and NMR spectroscopy. Despite, from our point of view, the new metabolites described here not 
providing new insights into the intriguing biogenetic origin of this class of molecules, their isolation 
does provide additional evidence of the currently accepted hypothesis regarding the biosynthesis of 
this family of natural products. 
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